trending Market Intelligence /marketintelligence/en/news-insights/trending/1j1r58uchbrqqmml5hfc5q2 content esgSubNav
In This List

CRISPR Therapeutics chief legal officer retires

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


CRISPR Therapeutics chief legal officer retires

Zug, Switzerland-based CRISPR Therapeutics AG said Tyler Dylan-Hyde retired as chief legal officer of the company.

Dylan-Hyde joined the company in January 2015.

The company develops gene-editing therapies for various diseases, including sickle cell disease and hemophilia.